Etiologi ved malignt melanom hva vet vi? Cutaneous malignant melanoma etiological factors

Tidsskrift for den Norske Laegeforening

Volumn 117, Issue 7, 1997, Pages 969-971

  Helsing, Per ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

GENETICS; HUMAN; MELANOMA; NEVUS; REVIEW; SKIN TUMOR;

HUMANS; MELANOMA; NEVUS; SKIN NEOPLASMS;

EID: 0031562170     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. I. 0sterlind A. Epidemiology on malignant melanoma in Europe. Reviews in Oncologica 1992; 5: 903-8.
2. Brozenza SJ, Fenske NA, Ferez IR. Epidemiology of malignant melanoma, worldwide incidence, and etiologic factors. Semin Surg Oncol 1993; 9: 165-7.
3. Rigel DS. Epidemiology and prognostic factors in malignant melanoma. Ann Plast Surg 1992; 28: 7-8.
4. Franceschi S, La Vecchia C, Lucchini F, Cristofolini M. The Epidemiology of cutaneous melanoma: actiologicy and European data. Eur J Cancer Prev 1991; 1:9-22.
5. Kraehn GM, Schart! M, Peter RU. Human malignant melanoma. A genetic disease? Cancer 1995; 75: 1228-37.
6. Meyer LJ, Zone JH. Genetics of cutaneous melanoma. J Invest Dermatol 1994; 103: 112-6.
7. Everett MA. The management of congenital nevi. J Okla State Med Assoc 1991; 84: 213-8.
8. Marghoob AA, Schoenbach SP, tCopf A, Orlow SJ, Nossa R, Bart RS. Large congenital melanocytic nevi and the risk for the development of malignant melanoma. Arch Dermatol 1996; 132: 170-5.
9. Ruiz-Maldonado R, Tamayo L, Laterza AM, Duran C. Giant pigmented nevi: clinical, histopathologic, and therapeutic considerations. J Pé diatrie 1992; 120: 906-11.
10. Swerdlow AJ, English JSC, Qiao Z. The risk of melanoma in patients with congenital nevi: a cohort study. J Am Acad Dermatol 1995; 32: 595-9.
11. Consensus development panel on early melanoma. Diagnosis and treatment of early melanoma. JAMA 1992; 268: 1314-9.
12. Halpern AC, Guerry D, Elder DE, Clark WH, Synnestvedt M, Norman S et al. Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. Arch Dermatol 1991; 127: 995-9.
13. Slade J, Marghoob AA. Salopek TG, Rigel TG, Kopf AW, Bart RS. Atypical mole syndrome: risk factor for cutaneous malignant melanoma and implications for management. J Am Acad Dermatol 1995; 32: 479-94.
14. Swerdlow AJ, English J, MacKie RM, O'Doherty CJ, Hunter JAA, Clark J et al. Benign melanocytic naevi as a risk factor for malignant melanoma. BMJ 1986; 292: 1555-9.
15. Holly EA, Kelly JW, Shpall SN, Chiu S-H. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma? J Am Acad Dermatol 1987; 17: 459-68.
16. Skender-Kalnenas TM, English DR, Heena PJ. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma? J Am Acad Dermatol 1995; 33: 1000-7.
17. Augustsson A, Stierner U, Rosdahl 1, Suurküla M. Melanocytic naevi in sun-exposed and protected skin in melanoma patients and controls. Acta Derm Venereol 1990; 71: 512-7.
18. Krüger S, Garbe C, Büttner P, Stadier R. Guggenmoos-Holzmann l, Orfanos CE. Epidemiologie evidence for the role of melanocytic nevi as risk markers and direct precursors of cutaneous malignant melanoma. J Am Acad Dermatol 1992; 26: 920-6.
19. 0sterlind A. Hudpigmentering, naevi og sollys som etiologiske faktorer til kutant malignt melanom. Nord Med 1990; 1105: 223-9.
20. Katsambas A, Nicolaidou E. Cutaneous malignant melanoma and sun exposure. Arch Dermatol 1996; 132: 444-50.
21. Moan J, Dahlback A. Ultraviolet radiation and skin cancer. I: Young AR, Bj0rn LO, Moan J, Nultsch W, red. Environmental phoiobiology. New York: Plenum Press, 1993: 255-93.
22. Green A. A theory of site distribution of melanomas: Queensland, Australia. Cancer Causes Control 1992; 3: 513-6.
23. Setlow RB, Grist E, Thomson K, Woodhead AD. Wavelengths effective in induction of malignant melanoma. Proc Natl Acad Sei 1993; 90: 6666-70.
24. Elwood JM. Melanoma and sun exposure: contrasts between intermittent and chronic exposure. World J Surg 1992; 16: 157-65.
25. Kirkpatrick CS, Lee JAH, White E. Melanoma risk by age and socio-economic status. Int J Cancer 1990; 46: 1-4.
26. Walter SD, Marret ED, From L, Hertzman C, Shannon HS, Roy P. The assosciation of cutaneous malignant melanoma with the use of sunbeds and sunlamps. Am J Epidemiol 1990; 131: 232-43.
27. 0sterlind A, Tucker MA, Stone BJ. The Danish case-control study of cutaneous malignant melanoma. 11. Importance of UV-light exposure. Int J Cancer 1988; 42: 319-24.
28. Westerdahl J, Olsson H, Masback A, Ingvar C, Jonsson N, Brandt E et al. Use of sunbeds or sunlamps and malignant melanoma in southern Sweden. Am J Epidemiol 1994; 140: 691-9.
29. Pack GT, Scharnagel IM. The prognosis for malignant melanoma in the pregnant woman. Cancer 1951; 4: 324-34.
30. Driscoll MS, Grin-Jorgensen CM, GrantKels JM. Does pregnancy influence the prognosis of malignant melanoma? J Am Acad Dermatol 193; 29: 619-30.
31. Holly EA, Cress RD, Ahn DK. Cutaneous melanoma in women. III. Reproductive factors and oral contraceptive use. Am J Epidemiol 1995; 141: 943-50.
32. Moan J. Er UVA ârsak til malignt melanom? Tidsskr Nor Lsegeforen 1994; 114: 935-8.
33. Whitmore SE, Morison WE. Prevention of UVB-induced immunosuppression in humans by a high sun protection factor sunscreen. Arch Dermatol 1995; 131: 1128-33.